Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.63 USD
Change Today -0.0281 / -4.28%
Volume 310.7K
RXII On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
Frankfurt
As of 1:52 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

rxi pharmaceuticals (RXII) Snapshot

Open
$0.66
Previous Close
$0.66
Day High
$0.66
Day Low
$0.62
52 Week High
09/3/14 - $3.98
52 Week Low
04/24/15 - $0.61
Market Cap
19.6M
Average Volume 10 Days
928.7K
EPS TTM
$-0.86
Shares Outstanding
31.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RXI PHARMACEUTICALS (RXII)

Related News

No related news articles were found.

rxi pharmaceuticals (RXII) Related Businessweek News

No Related Businessweek News Found

rxi pharmaceuticals (RXII) Details

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma. The company’s preclinical program includes the development of products for ocular indications with RXI-109, including retinal and corneal scarring. Its discovery stage development programs include a dermatology franchise for the discovery of collagenase and tyrosinase targets for its RNAi platform; and ophthalmology franchise, a program for the discovery of sd-rxRNA compounds for oncology indications, including retinoblastoma. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

15 Employees
Last Reported Date: 03/30/15
Founded in 2011

rxi pharmaceuticals (RXII) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $495.3K
Chief Development Officer
Total Annual Compensation: $413.6K
Compensation as of Fiscal Year 2014.

rxi pharmaceuticals (RXII) Key Developments

RXi Pharmaceuticals Corporation Presents at BioNetwork Partnering Summit, May-04-2015 12:05 PM

RXi Pharmaceuticals Corporation Presents at BioNetwork Partnering Summit, May-04-2015 12:05 PM. Venue: Trump International Beach Resort Miami, Sunny Isles Beach, Florida, United States. Speakers: Geert Cauwenbergh, Chief Executive Officer, President, Acting Chief Financial Officer, Director and Member of Corporate Governance Committee.

RXi Pharmaceuticals Receives Orphan Drug Designation for Samcyprone from U.S. FDA for Treatment of Malignant Melanoma Stage IIb to IV

RXi Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation of its second clinical candidate, Samcyprone, for the treatment of Malignant Melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases. Samcyprone is being developed for treatment of these metastases. Samcyprone is a topical formulation of Diphenylcylcopropenone in clinical development for the treatment of warts, alopecia areata and cutaneous metastases of melanoma. The mechanism of action for treatment cutaneous metastases of melanoma involves elicitation of an immune response in the skin that subsequently causes destruction of the cutaneous tumor. Melanomas, cancers that arise from melanocytes, are the most aggressive form of skin cancer. Once melanoma has spread beyond the localized area of the primary lesion, the survival rate decreases and melanoma becomes increasingly more difficult to treat successfully. Management of metastatic melanoma, including cutaneous metastases, is challenging and represents an area of great unmet need.

RXi Pharmaceuticals Seeks Acquisitions

RXi Pharmaceuticals Corporation (NasdaqCM:RXII) has filed a shelf registration in the amount of $20 million. RXi Pharmaceuticals said, "We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies or to fund the development of any such complementary businesses, products or technologies that we may acquire in a stock-based acquisition."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXII:US $0.63 USD -0.0281

RXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXII.
View Industry Companies
 

Industry Analysis

RXII

Industry Average

Valuation RXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 201.4x
Price/Book 12.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 82.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RXI PHARMACEUTICALS, please visit www.rxipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.